KMT2A and leukemia: With a Ki of 0.08 nM, pinometostat was nearly four-times more potent against DOT1L as EPZ004777, as well as displaying improved potency for inhibiting MLL-rearranged leukaemia cell proliferation, abrogating H3K79me2, and reducing the expression of MLL-fusion target genes.